Aclarion (ACON) Competitors $7.04 -0.01 (-0.14%) Closing price 08/28/2025 03:48 PM EasternExtended Trading$7.06 +0.02 (+0.28%) As of 08/28/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. BRTX, BGLC, MGRX, SSY, ATIP, DHAC, NIVF, OTRK, BACK, and BTTXShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Biorestorative Therapies (BRTX), BioNexus Gene Lab (BGLC), Mangoceuticals (MGRX), SunLink Health Systems (SSY), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), NewGenIvf Group (NIVF), Ontrak (OTRK), IMAC (BACK), and Better Therapeutics (BTTX). These companies are all part of the "healthcare" industry. Aclarion vs. Its Competitors Biorestorative Therapies BioNexus Gene Lab Mangoceuticals SunLink Health Systems ATI Physical Therapy Digital Health Acquisition NewGenIvf Group Ontrak IMAC Better Therapeutics Biorestorative Therapies (NASDAQ:BRTX) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Do institutionals & insiders hold more shares of BRTX or ACON? 69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 30.8% of Biorestorative Therapies shares are owned by insiders. Comparatively, 0.8% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor BRTX or ACON? In the previous week, Biorestorative Therapies and Biorestorative Therapies both had 1 articles in the media. Aclarion's average media sentiment score of 1.88 beat Biorestorative Therapies' score of 0.94 indicating that Aclarion is being referred to more favorably in the news media. Company Overall Sentiment Biorestorative Therapies Positive Aclarion Very Positive Which has preferable earnings and valuation, BRTX or ACON? Aclarion has lower revenue, but higher earnings than Biorestorative Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiorestorative Therapies$400K36.49-$8.98M-$1.27-1.44Aclarion$50K81.66-$6.99MN/AN/A Do analysts recommend BRTX or ACON? Aclarion has a consensus target price of $11,758.50, suggesting a potential upside of 166,924.15%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Biorestorative Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is BRTX or ACON more profitable? Biorestorative Therapies has a net margin of -1,772.40% compared to Aclarion's net margin of -11,238.59%. Aclarion's return on equity of -83.63% beat Biorestorative Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Biorestorative Therapies-1,772.40% -137.00% -88.31% Aclarion -11,238.59%-83.63%-76.55% Which has more volatility & risk, BRTX or ACON? Biorestorative Therapies has a beta of 76.7, suggesting that its share price is 7,570% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. SummaryAclarion beats Biorestorative Therapies on 7 of the 12 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.11M$7.69B$5.78B$9.79BDividend YieldN/A2.73%3.95%4.02%P/E RatioN/A78.2431.2626.59Price / Sales81.6645.61431.16158.34Price / CashN/A24.7637.7359.36Price / Book0.2921.7310.046.68Net Income-$6.99M$242.04M$3.27B$265.59M7 Day Performance-3.56%-0.92%1.34%0.66%1 Month Performance-8.69%2.64%6.13%2.64%1 Year Performance-99.64%9.98%41.90%22.36% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion2.2215 of 5 stars$7.04-0.1%$11,758.50+166,924.1%-99.7%$4.11M$50K0.007Positive NewsBRTXBiorestorative Therapies2.342 of 5 stars$1.54+1.3%N/A+8.9%$12.13M$400K-1.217BGLCBioNexus Gene Lab0.2337 of 5 stars$5.32-0.4%N/A+25.9%$9.59M$9.51M0.0030Positive NewsMGRXMangoceuticals0.5976 of 5 stars$1.57-4.6%N/A-95.4%$8.48M$620K-0.413Positive NewsSSYSunLink Health SystemsN/A$1.12+16.6%N/A+34.5%$7.88M$31.09M4.661,376Gap UpATIPATI Physical TherapyN/A$0.68flatN/A-88.4%$2.98M$741.86M-0.045,600DHACDigital Health AcquisitionN/A$0.78-9.1%N/A-49.4%$2.82MN/A0.002,021Gap UpNIVFNewGenIvf GroupN/A$1.91+0.5%N/A-99.8%$1.64M$5.43M0.00N/APositive NewsOTRKOntrak2.7115 of 5 stars$0.32-3.0%$3.00+837.5%-97.3%$1.39M$10.85M-0.02250Gap DownBACKIMACN/A$0.10+38.0%N/A-95.9%$203K$72.05K0.00180BTTXBetter TherapeuticsN/AN/AN/AN/A$5KN/A0.0040 Related Companies and Tools Related Companies Biorestorative Therapies Competitors BioNexus Gene Lab Competitors Mangoceuticals Competitors SunLink Health Systems Competitors ATI Physical Therapy Competitors Digital Health Acquisition Competitors NewGenIvf Group Competitors Ontrak Competitors IMAC Competitors Better Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access